Rich has spent more 40 years working as a scientist in the biotechnology industry joining companies in the start-up stages, including Biogen, CytoMed, UCB Research, GlycoFI, Ikano, Proclara Biosciences, FL60, and Vigil Neuroscience. He spent more than 15 years in neuroscience-focused drug discovery and development as Chief Scientific Officer, and led teams for discovery and early development of several drug candidates for neurodegenerative diseases and epilepsy. Rich received his BA (Zoology) and PhD (Microbiology and Molecular Genetics) from the University of Iowa and was an American Cancer Society postdoctoral fellow at the University of Chicago (Biophysics and Theoretical Biology).